graph EGM comparisons
pembrolizumab alonetitlepembrolizumab (10mg/kg)titlepembrolizumab plus SoCtitlepembrolizumab (10mg/kg) 2 weekstitlepembrolizumab (2mg/kg)titleplacebo plus SoCtitleplacebotitleipilimumab alonetitleStandard of Care (SoC)titleKEYNOTE-006 (3 week), 2015 NCT01866319 mML - L2 - all population 277/278KEYNOTE-002 (10 mg/kg), 2015 NCT01704287 mML - L2 - all population 181/179KEYNOTE-006 (2 week), 2015 NCT01866319 mML - L2 - all population 279/278KEYNOTE-002 (2 mg/kg), 2015 NCT01704287 mML - L2 - all population 180/179KEYNOTE-022, 2019 NCT02130466 mML - L2 - BRAF mutant 60/60KEYNOTE 054 (all population), 2018 NCT02362594 mML - NA - all population 514/505KEYNOTE 054 (PDL1>1%), 2018 NCT02362594 mML - NA - PDL1 positive 428/425

Pathology:  mML - L2 - all population;   mML - L2 - BRAF mutant;   mML - NA - all population;   mML - NA - PDL1 positive; 

mML - L2 - all populationmML - L2 - BRAF mutantmML - NA - all populationmML - NA - PDL1 positive
KEYNOTE-006 (3 week), 2015KEYNOTE-002 (10 mg/kg), 2015KEYNOTE-006 (2 week), 2015KEYNOTE-002 (2 mg/kg), 2015KEYNOTE-022, 2019KEYNOTE 054 (all population), 2018KEYNOTE 054 (PDL1>1%), 2018
pembrolizumab alone2T1T1
pembrolizumab (10mg/kg)2T1T1
pembrolizumab plus SoC1T1
pembrolizumab (10mg/kg) 2 weeks1T1
pembrolizumab (2mg/kg)1T1
placebo plus SoC0T0
placebo0T0T0
ipilimumab alone0T0T0
Standard of Care (SoC)0T0T0